Table 2.
PASC patients characteristics stratified by risk scores.
| Variables | Risk groups for OS | Risk groups for CSS | ||||
|---|---|---|---|---|---|---|
| High-risk group (n = 421) | Low-risk group (n = 211) | p value | High-risk group (n = 356) | Low-risk group (n = 276) | p value | |
| Age | 0.057 | 0.129 | ||||
| <65 years | 143 (34.0%) | 88 (41.7%) | 121 (34.0%) | 110 (39.9%) | ||
| ≥65 years | 278 (66.0%) | 123 (58.3%) | 235 (66.0%) | 166 (60.1%) | ||
| Gender | 0.674 | 0.316 | ||||
| Male | 216 (51.3%) | 112 (53.1%) | 165 (46.3%) | 137 (49.6%) | ||
| Female | 205 (48.7%) | 99 (46.9%) | 191 (53.7%) | 139 (50.4%) | ||
| Ethnicity | 0.505 | 0.813 | ||||
| White | 344 (81.7%) | 171 (81.0%) | 292 (82.0%) | 223 (80.8%) | ||
| Black | 47 (11.2%) | 20 (9.5%) | 38 (10.7%) | 29 (10.5%) | ||
| Other | 30 (7.1%) | 20 (9.5%) | 26 (7.3%) | 24 (8.7%) | ||
| Year of diagnosis | 0.664 | 0.421 | ||||
| 2000–2009 | 147 (34.9%) | 70 (33.2%) | 127 (35.7%) | 90 (32.6%) | ||
| 2010–2018 | 274 (65.1%) | 141 (66.8%) | 229 (64.3%) | 186 (67.4%) | ||
| Marital status | 0.001 | 0.001 | ||||
| Married | 237 (56.3%) | 159 (75.4%) | 196 (55.1%) | 200 (72.5%) | ||
| Unmarried | 184 (43.7%) | 52 (24.6%) | 160 (44.9%) | 76 (27.5%) | ||
| Tumor location | 0.055 | 0.036 | ||||
| Head | 191 (45.4%) | 113 (53.6%) | 159 (44.7%) | 145 (52.5%) | ||
| Body/tail | 160 (38.0%) | 76 (36.0%) | 135 (37.9%) | 101 (36.6%) | ||
| Other | 70 (16.6%) | 22 (10.4%) | 62 (17.4%) | 30 (10.9%) | ||
| Tumor size | 0.001 | 0.001 | ||||
| ≤2 cm | 13 (3.1%) | 8 (3.8%) | 9 (2.5%) | 12 (4.3%) | ||
| 2–4 cm | 131 (31.1%) | 110 (52.1%) | 100 (28.1%) | 141 (51.1%) | ||
| >4 cm | 277 (65.8%) | 93 (44.1%) | 247 (69.4%) | 123 (44.6%) | ||
| Tumor number | 0.082 | 0.015 | ||||
| Single | 406 (96.4%) | 197 (93.4%) | 346 (97.2%) | 257 (93.1%) | ||
| Multiple | 15 (3.6%) | 14 (6.6%) | 10 (2.8%) | 19 (6.9%) | ||
| Lymph node status | 0.001 | 0.001 | ||||
| Positive | 136 (32.3%) | 119 (56.4%) | 108 (30.3%) | 147 (53.3%) | ||
| Negative | 222 (52.7%) | 89 (42.2%) | 185 (52.0%) | 126 (45.6%) | ||
| Unknown | 63 (15.0%) | 3 (1.4%) | 63 (17.7%) | 3 (1.1%) | ||
| Bone involvement | 0.050 | 0.006 | ||||
| Yes | 10 (2.4%) | 0 | 10 (2.8%) | 0 | ||
| No | 257 (61.0%) | 140 (66.4%) | 212 (59.6%) | 185 (67.0%) | ||
| Unknown | 154 (36.6%) | 71 (33.6%) | 134 (37.6%) | 91 (33.0%) | ||
| Liver involvement | 0.001 | 0.001 | ||||
| Yes | 125 (29.7%) | 7 (3.3%) | 119 (33.4%) | 13 (4.7%) | ||
| No | 142 (33.7%) | 133 (63.1%) | 103 (28.9%) | 172 (62.3%) | ||
| Unknown | 154 (36.6%) | 71 (33.6%) | 134 (37.7%) | 91 (33.0%) | ||
| Lung involvement | 0.010 | 0.003 | ||||
| Yes | 15 (3.6%) | 0 | 14 (3.9%) | 1 (0.3%) | ||
| No | 249 (59.1%) | 140 (66.4%) | 205 (57.6%) | 184 (66.7%) | ||
| Unknown | 157 (37.3%) | 71 (33.6%) | 137 (38.5%) | 91 (33.0%) | ||
| SEER stage | 0.001 | 0.001 | ||||
| Localized | 33 (7.8%) | 25 (11.8%) | 25 (7.0%) | 33 (12.0%) | ||
| Regional | 147 (34.9%) | 149 (70.7%) | 106 (29.8%) | 190 (68.8%) | ||
| Distant | 241 (57.3%) | 37 (17.5%) | 225 (63.2%) | 53 (19.2%) | ||
| Surgery | 0.001 | 0.001 | ||||
| Yes | 82 (19.5%) | 211 (100%) | 34 (9.6%) | 259 (93.8%) | ||
| No | 339 (80.5%) | 0 | 322 (90.4%) | 17 (6.2%) | ||
| Radiation | 0.001 | 0.001 | ||||
| Yes | 6 (1.4%) | 76 (36.0%) | 1 (0.3%) | 81 (29.3%) | ||
| No | 415 (98.6%) | 135 (64.0%) | 355 (99.7%) | 195 (70.7%) | ||
| Chemotherapy | 0.001 | 0.001 | ||||
| Yes | 216 (51.3%) | 196 (92.9%) | 190 (53.4%) | 222 (80.4%) | ||
| No | 205 (48.7%) | 15 (7.1%) | 166 (46.6%) | 54 (19.6%) | ||
| Primary endpoint: OS, months | ||||||
| Median (95% CI) | 4.0 (3.38–4.62) | 15.0 (12.96–17.04) | 0.001† | 4.0 (3.48–4.52) | 13.0 (11.19-14.81) | 0.001† |
| Primary endpoint: CSS, months | ||||||
| Median (95% CI) | 4.0 (3.37–4.63) | 15.0 (12.77–17.23) | 0.001† | 4.0 (3.47–4.53) | 14.0 (11.96-16.04) | 0.001† |
†Log-rank test; Bold values indicate p < 0.05.